title: Children and autism--Part 1--recognition and pharmacological management.
abstract: BACKGROUND
  Autism is a neurodevelopmental disorder characterized by complex aetiology, variable presentation and widely divergent outcomes. It is clear that an individual's intrinsic genetic susceptibility, health, nutritional status and environmental exposures all contribute to the aetiology of autism.
  
  
  OBJECTIVE
  This article aims to assist the general practitioner in recognizing and managing a child with an autistic disorder.
  
  
  CONCLUSIONS
  Screening for autism by the GP can lead to referral for a formal diagnosis, enabling much needed support at an early stage of development, which can improve outcomes for the individual. Currently, evidence for psychotropic use and awareness of adverse effects in young people with autism is limited. Antipsychotic medications are increasingly used in people with autism and the importance of monitoring for adverse effects is paramount. Primary strategies for dealing with children with autism are understanding, environmental modification and behavioural interventions. Combined with these, pharmacological interventions may have benefits for children with autism with extreme or challenging behaviours.
authors.affiliation: Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, and Women's and Children's Hospital, Adelaide, South Australia, Australia. manya.angley@unisa.edu.au
authors.forename: Manya
authors.initials: M
authors.lastname: Angley
authors.forename: Robyn
authors.initials: R
authors.lastname: Young
authors.forename: David
authors.initials: D
authors.lastname: Ellis
authors.forename: Wilson
authors.initials: W
authors.lastname: Chan
authors.forename: Ross
authors.initials: R
authors.lastname: McKinnon
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use; D001321:Autistic Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002648:Child; D002669:Child Welfare; D002675:Child, Preschool; D005194:Family Practice / Q000379:methods; D006801:Humans; D008297:Male; D008403:Mass Screening; D011320:Primary Health Care; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D017367:Selective Serotonin Reuptake Inhibitors